Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.7%. By the end of trading, Valeant Pharmaceuticals International rose $1.87 (1.9%) to $97.59 on average volume. Throughout the day, 1,991,993 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,880,600 shares. The stock ranged in a price between $95.35-$97.70 after having opened the day at $96.78 as compared to the previous trading day's close of $95.72. Other companies within the Drugs industry that increased today were: Opexa Therapeutics ( OPXA), up 131.8%, iBio ( IBIO), up 24.9%, Oxygen Biotherapeutics ( OXBT), up 17.9% and GW Pharmaceuticals PLC ADR ( GWPH), up 15.8%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $31.7 billion and is part of the health care sector. Shares are up 60.1% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.

On the negative front, Mast Therapeutics ( MSTX), down 40.6%, Inovio Pharmaceuticals ( INO), down 26.1%, Aastrom Biosciences ( ASTM), down 21.4% and Ambit Biosciences ( AMBI), down 18.3% , were all laggards within the drugs industry with Onyx Pharmaceuticals ( ONXX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)